| 1 |
29632608 | The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration. | 2017 Aug |
2 |
| 2 |
27207543 | Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist. | 2016 Aug |
1 |
| 3 |
24612221 | Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. | 2014 Sep |
3 |
| 4 |
23110260 | Linagliptin as add-on therapy for type 2 diabetes - an overview. | 2012 Oct |
1 |
| 5 |
19275548 | Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. | 2009 Feb |
1 |
| 6 |
17947341 | Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. | 2008 Jan |
1 |
| 7 |
18095923 | Update: vildagliptin for the treatment of Type 2 diabetes. | 2008 Jan |
1 |
| 8 |
18269436 | The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. | 2008 Mar |
2 |
| 9 |
17596103 | Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. | 2007 |
1 |
| 10 |
17698900 | The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. | 2007 Nov |
3 |